Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alvogen Inks Agreement with Exeltis | Contract Pharma

What are you searching for?

Sign in
Breaking News

Alvogen Inks Agreement with Exeltis

Acquires a targeted portfolio of 23 prescription and OTC drugs in the field of women’s healthcare

By: Cassandra Gervolino

Alvogen has signed a definitive agreement with Exeltis, a division of the global pharmaceutical group Insud Pharma, to acquire a targeted portfolio of prescription and over-the-counter drugs in the field of women’s healthcare. The transaction includes 23 brands with marketing rights in Russia, Ukraine and Kazakhstan. Majority of the brands acquired will continue to be manufactured by Insud Pharma from their high-quality facilities in Spain and Turkey.

Hacho Hatchikian, Executive Vice President of Alvogen CEE, commented: “This transaction provides greater scale and diversity across our portfolio and sales channels, while increasing market share in women’s healthcare in key markets. The acquired brands will compliment, as well as significantly strengthen, Alvogen’s existing portfolio in the region.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics